Opus Genetics, Inc.
IRD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.02 | -0.01 | 0.01 |
| FCF Yield | -80.45% | -3.99% | 55.67% | -101.10% |
| EV / EBITDA | -0.35 | 2.27 | -0.93 | 0.09 |
| Quality | ||||
| ROIC | -242.79% | -21.19% | 38.73% | -99.76% |
| Gross Margin | 99.91% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.44 | 0.11 | 0.80 | 0.34 |
| Growth | ||||
| Revenue 3-Year CAGR | -34.90% | 218.60% | – | – |
| Free Cash Flow Growth | -2,200.00% | -107.77% | 173.90% | -184.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 5.07 | -2.34 | 0.42 |
| Interest Coverage | 0.00 | -7.95 | 2,025.11 | -11,352.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -114,710.34 | -130,929.46 | -97,501.83 | -144,540.00 |